Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aspirin resistance in stroke: 2004.

Laszlo K Sztriha1, Katalin Sas, Laszlo Vecsei

  • 1Department of Neurology, Albert Szent-Györgyi Medical and Pharmaceutical Center, University of Szeged, Szeged, Hungary.

Journal of the Neurological Sciences
|March 12, 2005
PubMed
Summary

Aspirin resistance, where aspirin fails to prevent thrombotic events, affects many patients. Understanding and addressing this resistance is key to improving cardiovascular disease outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial.

The Lancet. Neurology·2024
Same author

Fatal thrombolysis-related intracerebral haemorrhage associated with amyloid-β-related angiitis in a middle-aged patient - case report and literature review.

BMC neurology·2022
Same author

[B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].

Ideggyogyaszati szemle·2022
Same author

Editorial of Special Issue 'Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection'.

International journal of molecular sciences·2022
Same author

Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study.

Pharmaceuticals (Basel, Switzerland)·2022
Same author

Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer.

Journal of neural transmission (Vienna, Austria : 1996)·2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hematology

Background:

  • Aspirin is a cornerstone therapy for atherothrombotic vascular disease.
  • A significant subset of patients on aspirin experience recurrent ischemic events, indicating aspirin resistance.
  • Aspirin resistance is defined by the drug's inability to prevent thrombotic complications or achieve expected antiplatelet effects in lab tests.

Purpose of the Study:

  • To review the phenomenon of aspirin resistance in atherothrombotic vascular disease.
  • To discuss the implications of aspirin resistance for patient outcomes.
  • To explore potential mechanisms and management strategies for aspirin resistance.

Main Methods:

  • Literature review of studies on aspirin efficacy and resistance.

Related Experiment Videos

  • Analysis of laboratory techniques for assessing platelet function and aspirin response.
  • Examination of proposed mechanisms contributing to aspirin resistance.
  • Evaluation of alternative therapeutic strategies for aspirin-resistant patients.

    • Main Results:

    • Aspirin resistance is observed in 5-60% of patients, depending on the measure used.
    • Laboratory-confirmed aspirin resistance is associated with an increased risk of major vascular events.
    • Potential mechanisms include genetic factors, alternative platelet activation pathways, and drug interactions.
    • Increased aspirin dosage or switching to clopidogrel may benefit resistant patients.

    Conclusions:

    • Aspirin resistance poses a significant clinical challenge in managing atherothrombotic vascular disease.
    • Improved and validated laboratory tests are needed to guide personalized antiplatelet therapy.
    • Optimizing antiplatelet strategies is crucial for reducing premature vascular events.